Thursday, March 5, 2009

VOTE NOW !!!! Will the Feb. '09 vCJD scare in the UK affect your consideration of using a human or bovine sourced hemostat or sealant?


Currently I am offering 3 polls for open voting, if you are interested in offering an opinion I Thankyou! I will publish results later in the year, upon poll closure.
All Polls are located in the "side-bar". 
Thankyou and..............
As always I am available at hemostatguy@gmail.com
Thanks, HG

Irish Create Helpline Over Mad Cow fears









IRELAND - THE DISCOVERY that a haemophiliac who died in Britain last year had evidence of variant CJD or vCJD infection has led to just over 30 people ringing a helpline specifically set up to respond to the issue. The helpline was aimed at people who had received UK-derived plasma products or had concerns about blood products they received. Two information meetings were held in Dublin and Cork at the weekend to further allay concerns and were attended by a handful of people. It emerged two weeks ago that the elderly man, who did not die from vCJD, was infected from a UK plasma-derived product known as Factor VIII. Haemophilia and related bleeding disorders are caused by a lack of clotting factors and are treated by products containing clotting factor concentrate such as Factor VIII. Since the late 1990s, Ireland has been using a synthetic clotting concentrate. On hearing the details of the man’s death, the National Haemophilia director Dr Barry White and the Irish Haemophilia Society’s Brian O’Mahony wrote to the 50 Irish patients who had received UK plasma-derived products to inform them of developments. Only two of those had received a product that was subsequently identified as being at risk of vCJD. Thousands of people in the UK have received products where some of the donors developed vCJD, but none of the recipients have developed symptoms. There have been 167 cases of vCJD in the UK and four in Ireland since the link between eating infected meat and a new variant of CJD was made in the mid-1990s. Some nine people who died of vCJD in the UK had donated blood for the manufacture of clotting factor concentrates.

Orthovita Board of Directors Elects William Tidmore Chairman of the Board

The Board of Directors of Orthovita, Inc. (NASDAQ: VITA) has named William Tidmore Chairman of the Board of the Company effective March 3, 2009, following the resignation on March 1, 2009 of David Fitzgerald as Chairman of the Board and a director of Orthovita.

Mr. Tidmore has served as a member of Orthovita’s Board of Directors since 2007 and has over 20 years of experience in the spine and orthopedic industry. He was formerly President and Chairman of DePuy Acromed, as well as President of DePuy, which was acquired by Johnson & Johnson in 1999. Mr. Tidmore held various senior management positions during his tenure of over 14 years with Depuy, including leadership roles for international businesses with direct operational responsibilities across Europe, Latin America, Japan and Canada. Prior to that, Mr. Tidmore held several management positions at Ethicon, Inc., including Vice President of Sales and Marketing in Canada.

Mr. Fitzgerald, who had served since 2003 as Orthovita’s Chairman of the Board and as a member of the Board of Directors of ArthroCare Corp. (OTC:ARTC.PK), submitted his resignation to the Company due to his recent appointment as Acting President and Chief Executive Officer of ArthroCare. His decision to resign from Orthovita’s Board was based on the change in his role at ArthroCare to a senior executive, in recognition of the time commitment and possible business conflicts associated with this position.

“Dave has been an outstanding Chairman at Orthovita who has played an important role in the Company’s success throughout the years,” said Antony Koblish, President and Chief Executive Officer of Orthovita. “Under his guidance, Orthovita significantly increased sales, completed several key equity and debt financings, acquired marketing rights for two hemostasis products and made substantial progress in product development. We appreciate Dave’s contributions and he will be missed. We look forward to solid leadership from Bill Tidmore and the contributions that his extensive experience in the orthopedic and spine industry will bring.”

Thursday, February 26, 2009

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2008 - Edited


King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues equaled $1.57 billion during the year ended December 31, 2008, compared to $2.14 billion for 2007. In connection with its acquisition of Alpharma Inc. on December 29, 2008, King recorded a special charge in the amount of $590 million for acquired in-process research and development during the fourth quarter and year ended December 31, 2008. As result of this special charge, King reported a net loss of $333 million and a diluted loss per share of $1.37 during the year ended December 31, 2008, compared to net earnings of $183 million and diluted earnings per share of $0.75 during the prior year. Excluding special items, net earnings equaled $304 million and diluted earnings per share equaled $1.24 for the twelve months ended December 31, 2008, compared to net earnings of $476 million and diluted earnings per share of $1.95 in 2007.

THROMBIN-JMI(R) (thrombin, topical, bovine, USP) net sales totaled $57 million during the fourth quarter and $255 million for the year ended December 31, 2008, compared to $69 million during the fourth quarter and $267 million during the twelve months ended December 31, 2007. Net sales of THROMBIN-JMI(R) during 2008 were affected by a higher level of discounting due to increased competition. 

King will conduct a webcast today which may include discussion of the Company's marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business. The Company will also discuss some specific highlights of Alpharma's financial results for the fourth quarter and full year 2008. Interested persons may listen to the webcast on Thursday, February 26, 2009, at 11:00 a.m., E.S.T., by clicking the following link to register and then joining the live event with the same URL:

http://www.kingpharm.com/web_casts.asp 

Tuesday, February 24, 2009

Hemcon Expands Hemostasis Line

Hemcon announced Tuesday that its flexible hemostatic dressing HemCon Patch is now available for clinical settings. The dressing can be used for external, temporary control of bleeding during interventional and diagnostic cardiac catheterization, interventional radiology, electrophysiology and dialysis access procedures. Portland-based HemCon said offering diagnostic and interventional patients a quick, safe and comfortable post-procedural experience, the HemCon Patch delivers a flexible hemostatic solution where rapid arterial hemostasis is critically important to ensure quality care and safety. It reliably and quickly stops bleeding, minimizes risk of artery damage and frees up medical personnel. As one of the only hemostatic products to obtain an FDA antibacterial barrier claim, the HemCon Patch provides a barrier against a wide spectrum of micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis (VRE) and Acinetobacter baumannii.

Saturday, February 21, 2009

Thousands exposed to infection through clotting products


Thousands of patients with the bleeding disorder haemophilia have been exposed to successive viruses through treatment with clotting products made from donor blood and 1,757 have since died.

An independent inquiry, chaired by former solicitor general Lord Archer of Sandwell, is due to report on Monday into the contamination of blood and products made using blood.

In the 1970s and 1980s blood derivatives were sourced from within the UK and from the USA where donors were paid and often funded their drug habit through the payments. Blood was later found to be infected with Hepatitis C and later HIV and thousands became infected through using the products.

Successive governments have failed to acknowledge any fault and compensation has so far been limited to 'ex gratia payments', Lord Archer of Sandwell said at the opening of the inquiry in March 2007.

The inquiry is expected to recommend that further compensation payments be made to those who have contracted viruses and the families of those who have since died.

The report will also point to the new danger to haemophiliacs of vCJD as they may have been given products contaminated with the human form of mad cow disease before the 1998 ruling that all clotting factors should be sourced from outside the UK.

Earlier this week the Health Protection Agency confirmed the death of the first haemophiliac to have contracted vCJD from contaminated blood although this did not cause his death. The donor died six months after giving blood in 1996.

All patients with bleeding conditions were told in 2004 that they were at risk of having contracted vCJD from contaminated products that were administered between 1980 and 2001.

The inquiry was set up by Lord Morris of Manchester, who is president of the Haemophilia Society, who has fought for better treatment of patients infected with contaminated blood products for a number of years.

Former health minister Dr Lord Owen has given evidence along with patients, doctors and advocates.

In 1998 the Department of Health announced that plasma for clotting factors would be sourced from outside the UK and synthetic products were introduced for all patients in Scotland and Wales, but these were restricted to children under 16 only in England.

One of the patients who contracted hepatitis C through infected products, campaigner Peter Mossman, said: "I hope the inquiry will draw a line under this. We are all tired and what it over with."

The patients gave evidence that they have faced financial hardship since becoming infected with many becoming too ill to work and they have argued they cannot get health insurance because of their condition.

 

Friday, February 20, 2009

Cryolife edited - Q4

BioGlue surgical adhesive revenues were $12.1 million for the fourth quarter of ’08 compared to $11.5 million for the fourth quarter of ’07, an increase of 5%. This increase was primarily due to an increase in average selling prices, which increased revenues by 5% and a 3% increase in the number of BioGlue milliliters that shipped which increased revenues by 2%, offset by the unfavorable impact of foreign exchange which reduced revenues by 2%.

BioGlue revenues were a record $48.6 million for the full year of ’08, compared to $43.9 million for the full year of ’07, an increase of 11%. This increase was due to an increase in average selling prices, which increased revenues by 6% and a 5% increase in the number of BioGlue milliliters shipped, which increased revenues by 5%.

Also during the fourth quarter, we saw little push back on pricing for customers, again, due to current economic conditions and the resulting budgetary pressures of hospitals. Additionally, we saw a continuing strengthening of the dollar versus the British pound and the euro. For the full year of 2008 we generated $3.2 million in revenues, denominated in euros and $1.4 million in revenues denominated in British pounds. If the dollar continues to strengthen against the euro and pound we would expect this to have an adverse affect on our 2009 forecast revenues and gross margin. Additionally, it will be more expensive for our foreign customers who purchase product from us in US dollars. We expect that these factors, along, along with the growing contribution of Hemostase, which has a gross margin in the upper 50% range, will cause margins to decrease slightly during 2009.

We expect total revenues for the full year of ’09 to be between $113 and $119 million. We expect tissue processing revenues to be between $58 and $60.5 million and BioGlue revenues to be between $50 and $52 million for the full year of ‘09. Other medical device revenues, which consist primarily of sales of Hemostase, are expected to be between $4.5 and $4.5 million in ’09.

Other revenues for ’09 may reach between $0.5 and $1 million related to funding received from the Department of Defense in connection with the development of BioFoam. The amount of other revenues is largely dependant upon actual expenses incurred related to the development of BioFoam.


Wednesday, February 18, 2009

AMS get USA approval for Liquiband

HEALTHCARE technology company Advanced Medical Solutions (AMS) has reached a key milestone in its evolution by securing permission to market its products in America.The £16.9m turnover business, based in Winsford, Cheshire, has been given clearance for one of its major ranges of skin healing products called LiquiBand. The announcement opens AMS to a US market which is worth an estimated £140m a year, and the news prompted its shares to rise by 4.5 per cent or 1.5p to 35p. They later settled at 34.75p, a rise of 3.37 per cent.The deal also prompted analysts to predict a future target share price of 45p.While the LiquiBand range reduces the need for surgical stitches by `gluing' wounds together, some of its other products contain a derivative of seaweed to promote healing or silver to fight the spread of diseases.AMS is still seeking clearance for its other products in America which will ultimately provide it with an even stronger foothold in both accident and emergency departments and operating rooms.AMS chief executive Dr Don Evans said: "I am delighted that we have received this initial clearance on the back of which we will be finalising commercial arrangements for the introduction of our tissue adhesive technology to this key strategic market during 2009."AMS has already established a leading position in Britain and Europe with its LiquiBand range.Elizabeth Klein, of analyst Teathers, said: "We continue to highlight AMS as one of our top picks due to its good cash position - with no debt, its robust end markets, good relationships with partners and an expectation that new product approvals could additionally drive growth."

Nycomed's Tachosil receives expanded indication

•Surgical patch TachoSil® – first and only dual action patch for general tissue sealing
ZURICH, Switzerland, Feb. 17, 2009--Today Nycomed received an expanded indication for TachoSil®, its innovative surgical patch, from the European Medicines Agency (EMEA). To date, TachoSil was approved for haemostasis (control of bleeding) in surgery. With the new expanded indication, it becomes the first and only dual action patch approved for haemostasis, tissue sealing as well as for suture support in vascular surgery.
TachoSil is the key product in Nycomed’s tissue management portfolio and effectively fulfils the market need for a ready-to-use surgical patch, developed to assist surgeons in achieving fast and reliable bleeding control. Now, with the new expanded indication, Nycomed can offer a dual action patch approved for haemostasis, tissue sealing as well as for suture support in vascular surgery.
“With the expansion of TachoSil’s indication, Nycomed will bring the benefits of this unique product to surgical teams and those patients undergoing lung or other types of surgery requiring rapid air or body fluid sealing,” said Lone Nørgaard Andersson, International Brand Manager at Nycomed.
The new indication was filed with the EMEA in 2008, based on international clinical trial results on lung and cardiovascular surgery. TachoSil is currently available in Europe and Russia/CIS. In the United States, the product will be marketed by Baxter International Inc., while Nycomed will manufacture it and be responsible for the US regulatory filing.

Tuesday, February 17, 2009

First man dies after contracting 'mad cow disease' from clotting agent

The first case of a person dying after contracting the human form of mad cow disease from a blood clotting agent will be announced today.
The elderly man was one of thousands of haemophiliacs who received a blood plasma transfusion before strict rules were introduced to limit the spread of the deadly disease.
Up to 4,000 haemophilia sufferers have been warned that they could be at risk from the donations.
However, they were told that they had a low risk of contracting the variant Creutzfeldt-Jakob disease (vCJD) disease.
The Health Protection Agency will announce on Tuesday that the man, who died from other causes, did contract vCJD from the transfusion.
Prof Marc Turner, scientific director of the Scottish National Blood Transfusion Service, called for samples from vCJD patients to be released so that a test being developed by the company Amorfix to diagnose the disease before death could be perfected.
He told the BBC's Newsnight programme: "The two key things that need to be done are that the Amorfix test needs to be tested against the blood of patients with clinical vCJD in order to determine it can pick up positivity in that context and in parallel what we need to do is look at 10,000 blood samples from healthy individuals from both this country and America in order to determine the false positive rates and I would think that would take in the order of three to six months to carry out."
The blood test could be being used to screen Britain's blood supply within 18 months, he said.
To date 167 people have died from vCJD in Britain since it was first diagnosed in the mid-1990s.
But scientists warn that thousands of people could still go on to develop the disease because of the length of time it can remain in the body with no symptoms.
There have previously been three deaths following infection with vCJD linked to blood transfusions but this is the first of a patient who received plasma, which is used to clot blood and is crucial for people suffering from haemophilia.
All plasma is now sourced from America, where only a handful of cases of the disease have been identified.
Source: Telegraph.co.uk